Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Exemption to Pharma Companies for R&D (India)

This article was originally published in PharmAsia News

Executive Summary

Ram Vilas Paswan, India's Union Chemicals and Fertilizer Minister, announced that the government is committed to giving the country's pharmaceutical companies up to a 150 percent margin for research and development. Paswan hopes doing so will encourage drug-makers to further lower the prices on essential medications. At the same time, Paswan said the current price controls instituted by the country are not enough. He turned a deaf ear to the industry's argument that the prices for many drugs in India are much lower than most countries. According to Paswan, drugs must be less expensive in India because 80 percent of the country's population must pay for medications themselves. To further help the situation, the government is also planning to introduce health insurance for many of India's poorest citizens. (Click here for more

You may also be interested in...



QUOTED. 24 November 2020. Kees Wesdorp.

Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.

Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue

Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.

US FDA’s Unapproved Drug Initiative Nixed, But Without Agency Buy-In Demise May Be Short-Lived

Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.

UsernamePublicRestriction

Register

LL1134786

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel